ReviewWorld journal of gastroenterology2014
Immune responses to Helicobacter pylori infection.
Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 3 syntheses or guidelines pooled it, 117 citations in OpenAlex.
- Mucosal immune response in biology, disease prevention and treatment.Signal transduction and targeted therapy · 2025Pooled it
- Comprehensive Integration of Genome-Wide Association and Gene Expression Studies Reveals Novel Gene Signatures and Potential Therapeutic Targets forFrontiers in immunology · 2021Pooled it
- Helicobacter pylori infection and atopic diseases: is there a relationship? A systematic review and meta-analysis.World journal of gastroenterology · 2014Pooled it
- Therapy with omeprazole modulates regulatory T cell/T helper 17 immune response in children with duodenal ulcers.Inflammopharmacology · 2018Trial
- Efficacy and safety of live combined Bacillus subtilis and Enterococcus faecium in patients with Helicobacter pylori infection: A meta-analysis of randomized controlled trials.Clinics (Sao Paulo, Brazil) · 2026Review
- Mitochondrial Stress inAntioxidants (Basel, Switzerland) · 2026Review
- Integrated multi-omics profiling reveals phenotype- and tissue-specific host-microbiota interactions in paired tumor and peritumoral tissues of advanced gastric cancer patients from Northwest China.Frontiers in cellular and infection microbiology · 2026Article
- Navigating the gastric frontier of mucosal immunity againstFrontiers in immunology · 2026Review
- Clinical management of gastric mucosa-associated lymphoid tissue lymphoma.The Korean journal of internal medicine · 2026Review
- Ethyl Acetate Fraction fromJournal of microbiology and biotechnology · 2025Article
- Chitosan-based formulations for therapeutic applications. A recent overview.Journal of biomedical science · 2025Review
- The urease E subunit vaccine stimulate the immune response versus Helicobacter pylori in animal model.Immunologic research · 2025Article
- Effect ofImmunotherapy · 2025Review
- Effects of a combination of bifidobacteria quadruple viable bacteria tablets and quadruple therapy on inflammatory response andFrontiers in medicine · 2025Article
- Construction and evaluation of aFrontiers in immunology · 2025Article
- Article
- Role of the Microbiome in the Diagnosis and Management of Gastroesophageal Cancers.Journal of gastrointestinal cancer · 2024Review
- Critical role of the gut microbiota in immune responses and cancer immunotherapy.Journal of hematology & oncology · 2024Review
- Differential cytokine expression in gastric tissues highlights helicobacter pylori's role in gastritis.Scientific reports · 2024Article
- Antibodies directed against bacterial antigens in sera of Polish patients with primary biliary cholangitis.Frontiers in cellular and infection microbiology · 2024Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Helicobacter pylori (H. pylori) infection is one of the most common infections in human beings worldwide. H. pylori express lipopolysaccharides and flagellin that do not activate efficiently Toll-like receptors and express dedicated effectors, such as γ-glutamyl transpeptidase, vacuolating cytotoxin (vacA), arginase, that actively induce tolerogenic signals. In this perspective, H. pylori can be considered as a commensal bacteria belonging to the stomach microbiota. However, when present in the stomach, H. pylori reduce the overall diversity of the gastric microbiota and promote gastric inflammation by inducing Nod1-dependent pro-inflammatory program and by activating neutrophils through the production of a neutrophil activating protein. The maintenance of a chronic inflammation in the gastric mucosa and the direct action of virulence factors (vacA and cytotoxin-associated gene A) confer pro-carcinogenic activities to H. pylori. Hence, H. pylori cannot be considered as symbiotic bacteria but rather as part of the pathobiont. The development of a H. pylori vaccine will bring health benefits for individuals infected with antibiotic resistant H. pylori strains and population of underdeveloped countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.